Journal of Clinical Endocrinology & Metabolism, Vol 81, 1267-1272, Copyright © 1996 by Endocrine Society

ARTICLES

Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis

M Couce, TD O'Brien, A Moran, PC Roche and PC Butler
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA.

A high proportion of patients with cystic fibrosis (CF) develop diabetes mellitus. In common with type II diabetes mellitus, diabetes mellitus in CF is characterized by a progressive decline in beta-cell function and an approximately 50% decline in beta-cell mass. It is not known whether islet amyloidosis (characteristic of type II diabetes mellitus) is present in diabetes mellitus complicating CF. To address this, pancreatic samples were obtained at autopsy from 9 control cases (without CF) and 41 cases of CF that were, in turn, subdivided into 13 nondiabetic, 12 borderline diabetic, and 16 diabetic cases based on clinical criteria. Islet amyloid was detected by light microscopy in 69% cases of CF with diabetes mellitus, 17% of cases with borderline diabetes mellitus, and none of the nondiabetic cases. Islet amyloid was not present in any of the control cases. Islet amyloidosis derived from islet amyloid polypeptide is a characteristic feature of diabetes mellitus in CF as well as type II diabetes mellitus.

This article has been cited by other articles:

				L. Haataja, T. Gurlo, C. J. Huang, and P. C. Butler Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis Endocr. Rev., May 1, 2008; 29(3): 303 - 316. [Abstract] [Full Text] [PDF]

				C.-j. Huang, L. Haataja, T. Gurlo, A. E. Butler, X. Wu, W. C. Soeller, and P. C. Butler Induction of endoplasmic reticulum stress-induced -cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1656 - E1662. [Abstract] [Full Text] [PDF]

				V. Preumont, M. P. Hermans, P. Lebecque, and M. Buysschaert Glucose Homeostasis and Genotype-Phenotype Interplay in Cystic Fibrosis Patients With CFTR Gene {Delta}F508 Mutation Diabetes Care, May 1, 2007; 30(5): 1187 - 1192. [Abstract] [Full Text] [PDF]

				J. G. Geisler, W. Zawalich, K. Zawalich, J. R.T. Lakey, H. Stukenbrok, A. J. Milici, and W. C. Soeller Estrogen Can Prevent or Reverse Obesity and Diabetes in Mice Expressing Human Islet Amyloid Polypeptide Diabetes, July 1, 2002; 51(7): 2158 - 2169. [Abstract] [Full Text] [PDF]

				A. Moran, J. Phillips, and C. Milla Insulin and Glucose Excursion Following Premeal Insulin Lispro or Repaglinide in Cystic Fibrosis-Related Diabetes Diabetes Care, October 1, 2001; 24(10): 1706 - 1710. [Abstract] [Full Text] [PDF]

				A. Moran, C. Milla, R. Ducret, and K. S. Nair Protein Metabolism in Clinically Stable Adult Cystic Fibrosis Patients With Abnormal Glucose Tolerance Diabetes, June 1, 2001; 50(6): 1336 - 1343. [Abstract] [Full Text]